About Hanxin & SOFU
SOFU presents the peptide API raw-material, custom-development and manufacturing capabilities of Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
An integrated pharmaceutical platform
Founded from an R&D team established in 2009, Hanxin focuses on the full industrial chain for peptide, protein and polysaccharide raw materials and finished products, integrating research, production and commercialization.
Raw materials are our primary focus
The public SOFU catalog emphasizes peptide and API raw-material powders for qualified B2B and research cooperation. Selected premix products and formulation capabilities complement this core raw-material portfolio.
Research and manufacturing at scale
The platform includes 200+ R&D professionals, a 13,000 m² modern R&D base and a 200,000 m² GMP production base. Capabilities cover peptide APIs, recombinant biologics, formulation development and commercial manufacturing.
Regulatory and global experience
The company profile records regulatory experience in China, the United States and Europe, seven FDA inspections of the ANP production platform from 2014 to 2025, domestic CNAS certification and preparation cooperation in more than 30 countries.
Products and services
Core services include peptide APIs, custom peptide development, analytical and registration support, scalable manufacturing and selected premix products. Website catalog products remain strictly for qualified laboratory research use unless expressly stated otherwise.
